Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher L Bowlus

Showing results (131-140 of 189) with videos related to

Pageof 19
Sort By:
Hepatology (Baltimore, Md.)|November 22, 2007
Quality of life and everyday activities in patients with primary biliary cirrhosisCarlo Selmi, M Eric Gershwin, Keith D Lindor, et al.
Metabolites|February 25, 2022
Plasma Oxylipin Profile Discriminates Ethnicities in Subjects with Non-Alcoholic Steatohepatitis: An Exploratory AnalysisTagreed A Mazi, Kamil Borkowski, Oliver Fiehn, et al.
Free Radical Biology & Medicine|June 28, 2021
Ethnicity-specific alterations of plasma and hepatic lipidomic profiles are related to high NAFLD rate and severity in Hispanic Americans, a pilot studyTagreed A Mazi, Kamil Borkowski, John W Newman, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|October 14, 2019
Long-Term Obeticholic Acid Therapy Improves Histological Endpoints in Patients With Primary Biliary CholangitisChristopher L Bowlus, Paul J Pockros, Andreas E Kremer, et al.
Hepatology (Baltimore, Md.)|December 31, 2013
IL-12/Th1 and IL-23/Th17 biliary microenvironment in primary biliary cirrhosis: implications for therapyChen-Yen Yang, Xiong Ma, Koichi Tsuneyama, et al.
BMC Gastroenterology|March 16, 2023
PRIMIS: design of a pivotal, randomized, phase 3 study evaluating the safety and efficacy of the nonsteroidal farnesoid X receptor agonist cilofexor in noncirrhotic patients with primary sclerosing cholangitisMichael Trauner, Chuhan Chung, Kate Sterling, et al.
Hepatology Communications|March 13, 2019
A Randomized, Controlled, Phase 2 Study of Maralixibat in the Treatment of Itching Associated With Primary Biliary CholangitisMarlyn J Mayo, Paul J Pockros, David Jones, et al.
Hepatology (Baltimore, Md.)|July 22, 2014
Ongoing activation of autoantigen-specific B cells in primary biliary cirrhosisJun Zhang, Weici Zhang, Patrick S C Leung, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|August 7, 2022
Safety and Sustained Efficacy of the Farnesoid X Receptor (FXR) Agonist Cilofexor Over a 96-Week Open-label Extension in Patients With PSCMichael Trauner, Christopher L Bowlus, Aliya Gulamhusein, et al.
Journal of Hepatology|June 22, 2010
Impaired homocysteine transsulfuration is an indicator of alcoholic liver diseaseValentina Medici, Janet M Peerson, Sally P Stabler, et al.
Pageof 19

Showing results (131-140 of 189) with videos related to

Sort By:
Pageof 19
Hepatology (Baltimore, Md.)|November 22, 2007
Quality of life and everyday activities in patients with primary biliary cirrhosisCarlo Selmi, M Eric Gershwin, Keith D Lindor, et al.
Metabolites|February 25, 2022
Plasma Oxylipin Profile Discriminates Ethnicities in Subjects with Non-Alcoholic Steatohepatitis: An Exploratory AnalysisTagreed A Mazi, Kamil Borkowski, Oliver Fiehn, et al.
Free Radical Biology & Medicine|June 28, 2021
Ethnicity-specific alterations of plasma and hepatic lipidomic profiles are related to high NAFLD rate and severity in Hispanic Americans, a pilot studyTagreed A Mazi, Kamil Borkowski, John W Newman, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|October 14, 2019
Long-Term Obeticholic Acid Therapy Improves Histological Endpoints in Patients With Primary Biliary CholangitisChristopher L Bowlus, Paul J Pockros, Andreas E Kremer, et al.
Hepatology (Baltimore, Md.)|December 31, 2013
IL-12/Th1 and IL-23/Th17 biliary microenvironment in primary biliary cirrhosis: implications for therapyChen-Yen Yang, Xiong Ma, Koichi Tsuneyama, et al.
BMC Gastroenterology|March 16, 2023
PRIMIS: design of a pivotal, randomized, phase 3 study evaluating the safety and efficacy of the nonsteroidal farnesoid X receptor agonist cilofexor in noncirrhotic patients with primary sclerosing cholangitisMichael Trauner, Chuhan Chung, Kate Sterling, et al.
Hepatology Communications|March 13, 2019
A Randomized, Controlled, Phase 2 Study of Maralixibat in the Treatment of Itching Associated With Primary Biliary CholangitisMarlyn J Mayo, Paul J Pockros, David Jones, et al.
Hepatology (Baltimore, Md.)|July 22, 2014
Ongoing activation of autoantigen-specific B cells in primary biliary cirrhosisJun Zhang, Weici Zhang, Patrick S C Leung, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|August 7, 2022
Safety and Sustained Efficacy of the Farnesoid X Receptor (FXR) Agonist Cilofexor Over a 96-Week Open-label Extension in Patients With PSCMichael Trauner, Christopher L Bowlus, Aliya Gulamhusein, et al.
Journal of Hepatology|June 22, 2010
Impaired homocysteine transsulfuration is an indicator of alcoholic liver diseaseValentina Medici, Janet M Peerson, Sally P Stabler, et al.
Pageof 19